Sernova Corp T.SVA

Alternate Symbol(s): SEOVF

Healthcare Biotechnology

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.

TSX:SVA - Post by User

Sernova Corp

Bullboard Posts

Post by jwalliscaon Apr 05, 2020 5:13pm

170 Views

Post# 30881163

Sernova (SVA - TSXV) $$ progression... :(

SVA has had a very choppy closing price trading history, see five year chart. SVA has meandered from low teens (present price) to as high as almost 50 cents for a closing price over the last five years. Intrepid shareholders know Sernova is all about The Pouch (to treat numerous human complaints), "factors" (e.g. hemophilia) and stem type cells for various applications!

SVA closing share price chart; choose five years

Going back to 2015, we get no apparent correlation between news and share price save some of the peaks happened when news was released followed by a drop in price.... This is similar to what we keep seeing "today".

This lack of correlation with news continued into 2016. In late May 2016, the share price spiked on no news, but a PP that closed end of June saw a sharp dip at that time.

News, 12 July, 2016, on money from JDRF to fund the FDA trial for Type I diabetes coincided with a price spike and subsequent price drop. This decline continued as a slow erosion to mid-October 2017 regardless of any news.

We then got a major leg up on no news until, 11 Dec 2017, with news of FDA approval to start the trial. This resulted in a peak, fallback and then continued uptrend to a peak of 49.5 cent, 4 Jan 2018.

The share price then slowly eroded with an intermediate spike at 44 cents, 22 Feb 2018, on news Medtronic's instrumentation would be used in the FDA trial.

The share price continued to decline until a spike to 37 cents, 14 May 2018, on news U of Chicago approved the go ahead for the trial.

The share price then started to drop quickly. The reason turned out to be a PP at $0.25 that closed 23 July 2018. The share price continued to fall regardless of news of any kind until a close of 15 cents, 26 March 2019.

The share price started to rally and peaked at 26 cents, 3 July, 2019, on scientifically worded news that The Pouch was working AOK. The share price then declined to a close of 17 cents, 1 August, 2019. A PP was announced in late July 2019.

The share price started to rally and climbed to a close of 28 cents, 2 October, 2019 (about the time ViaCyte announced news on C-Peptides). Sernova responded 16 October, 2019, but the share price rallied slightly only to close at 25 cents.

There was a small rally (no news) to close at 21 cents, 4 Dec, 2019. The share price declined to 6 Feb, 2020 and then rallied to peaks of 20 cents, 12 - 14 Feb, 2020, on good news, 13 Feb, 2020, on the long overdue status of the Sentinel pouch.

Since then, COVID-19 has been hurting the markets badly and everything has fallen out of bed in sympathy. The excellent technical news, 24 March, 2020, resulted in a muted rally to 12.5 cents and a close of 11.5 cents.

Sernova news; pages 1 to 5 are available

The above share price vs news timeline clearly shows shareholders and interested parties in Sernova want FDA trial news badly. Further, it appears that news may need a better story flow in addition to the scientific slant to be better received by the market. To be sure pharmaceutical companies understand the science, but shareholders need "the vernacular" to get the significance.

My conjecture (like for both TRIL and BLU) is nothing and then something for Sernova's share price (SVA - TSXV). A major share price move now requires either a significant collaboration, or a complete Buy, Bye.